

PwC ALLG Tissue Bank

Total Holdings as of 31st December 2009

(34,146 samples available from 1378 consented patients with confirmed haematologic malignant disease)

Please note for the following slides:

- The sample numbers detailed under each WHO classification are made up of both diagnostic (Dx) and follow up (F/U) collections. Thus serial samples sets are available.
- The samples numbers listed under each classification are against total patient numbers - this does not imply that every patient has every sample type listed.
- The sample types listed have been processed from bone marrow aspirate (BM) and/or peripheral blood (PB) specimens. For most patients, BM and PB specimens are collected at each subsequent collection date.
- For further detail on specific holdings or for a more comprehensive breakdown of specimen /sample types available for your research project, please contact the Tissue Bank Manager directly.

Megan Ellis – ALLG Tissue Bank Manager
Princess Alexandra Hospital - QLD

Ph: (07) 3176 5835 or

megan_ellis@health.qld.gov.au

Tissue Bank Holdings by Diagnosis to 31st Dec 2009

– please see further graphs for breakdown

WHO - Major classification (non trial and trial)	Tissue Bank CODE	No. of samples	No. of patients
Acute Myeloid Leukaemia	AML	16,322	419
B-cell Neoplasms	B NEO	9372	511
Chronic Myeloproliferative Diseases	CMPD	4517	186
T-cell and NK-cell neoplasms	T/NK	1427	36
Myelodysplastic syndromes	MDS	1201	79
Hodgkin Lymphoma	HD	355	107
Myelodysplastic/Myeloproliferative Diseases	MDS/MPD	662	26
Miscellaneous	MISC	164	10
Immunodeficiency associated lymphoproliferative disorders	IDALPD	113	3
Histiocytic and dendritic cell neoplasms	HIST	0	0
Mastocytosis	MAST	13	1
Total		34,146	1378

AML 'Non Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are from BM, PB or both per patient

Acute Myeloid Leukaemia (AML) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Serum	Total Sample Numbers	Total Patient Numbers
AML with trilineage dysplasia	AML/TLD	29	2	7	7	1	22	68	4
AML with abnormal BM eosinophils	AML M16	18		3	6	1	6	34	2
AML with t(8;21)	AML821	29		2			18	49	2
AML with multilineage dysplasia WITH prior myelodysplasia	AMLAMDS	139	4	50	50	9	133	385	15
AML with multilineage dysplasia WITHOUT prior myelodysplasia	AMLDN	143	4	40	63	7	124	381	7
M0	AML M0/M0	146	5	42	22	3	124	342	10
M1	AML M1/M1	494	23	173	254	8	336	1288	25
M2	AML M2/M2	589	25	157	245	14	393	1423	37
M3 or APML	AML M3/M3 / APML	850	9	49	269		721	1898	24
M4	AML M4/M4	261	10	74	62	2	145	554	16
M5	AML M5/M5	305	15	109	195	4	160	788	20
M6	AML M6/M6	66	1	3	15	3	72	160	8
M7	AML M7/M7	6	3		2		12	23	2
Biphenotypic Leukaemia	BAL	110	5	19	25	2	102	263	7
No Classification has been recorded	NO CLASS	419	26	74	154		301	974	31
New WHO - AML with myelodysplastic changes	AMDRC	57			22	1	35	115	5
New WHO – AML – Blastic plasmacytoid dendritic cell neoplasm	BPDC	32		9	20		20	81	1
'AML' TOTAL		3693	132	811	1411	55	2724	8826	216

AML 'Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are processed from either BM or PB specimens or both per patient.

These samples are from tissue bank consented trial patients. Excess samples above MRD requirements were processed & stored and are available for approved researchers

AML 'Trial' Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Serum	Total Sample Numbers	Total Patient Numbers
APML4 TOTAL	AMPL4	199	3	14	51		101	368	10
AML9 TOTAL	AML9	30		31	18		5	84	5
AML10 TOTAL	AML10	27	6	18	11		12	74	4
AML12 TOTAL	AML12	1738	6	608	613	12	1733	4710	151
AML13 TOTAL	AML13	972	1	171	361		755	2260	33
TOTAL		2966	16	842	1054	12	2606	7496	203
GRAND TOTAL ('AML' Trial and Non Trial)		6659	148	1653	2465	67	5330	16322	419

B NEO 'Non Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points. Samples no's are from BM, PB or both per patient

B-CELL NEOPLASM 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Tissue	Seru m	Total Sample Numbers	Total Patient Numbers
Precursor B Lymphoblastic Leukaemia/Lymphoma	PB ALL	865	18	191	316		1	571	1962	45
Burkitt Lymphoma	BL	44	6	6	14		6	23	99	7
B-cell Prolymphocytic Leukaemia	BPLL	34		41	46			8	129	2
Chronic Lymphocytic Leukaemia	CLL	321		187	164	28		124	824	38
Chronic Lymphocytic Leukaemia/Prolymphocytic Leukaemia	CLL/PLL	23		17	15		1	10	66	2
Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma	CLL/SLL	179		60	120		2	76	437	13
Small Lymphocytic Lymphoma	SLL	32			10		3	18	63	5
Chronic Lymphocytic Leukaemia/ Richter's transformation DLBCL	CLL/RTDLB	27			20			11	58	1
Diffuse Large B-Cell Lymphoma	DLBCL	219		10	101		24	104	458	25
Diffuse Large B-Cell Lymphoma - transformed	DCBCLT						1		1	1
Follicular Lymphoma	FL	238		10	96		45	145	534	40
Follicular lymphoma - uninvolved BM	FLUB	4					1	5	10	2

B NEO 'Non Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points. Samples no's are from BM, PB or both per patient

B-CELL NEOPLASMS 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Tissue	Serum	Total Sample Numbers	Total Patient Numbers
Low Grade Lymphoma - not otherwise specified	LGLNOS	47			26			27	100	6
Hairy Cell Leukaemia	HCL	32		1	6			32	71	5
Lymphoplasmacytic Lymphoma	LPC	190		10	38			124	362	25
Light and/or Heavy Chain Disease	LHCD	12			6			5	23	2
Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Tissue	MALT	11			4			8	23	1
Mantle Cell Lymphoma	MCL	152		11	43		12	77	295	18
Mantle Cell Lymphoma - Blastoid variant	MCLBV	21	1	7	6			21	56	3
Monoclonal Gammopathy of Uncertain Significance	MGUS	319		25	135			160	639	49
Plasma Cell Myeloma	MM	797		51	259			435	1542	95
Nodal Marginal Zone B-Cell Lymphoma	MZL	68		21	23		9	25	146	11
NEW WHO - Large B cell Lymphoma arising in HHV8-associated multicentric Castleman Disease	NW-HHV8 MCD	9			1			7	17	1
Primary Amyloidosis	PA	3			3			4	10	1
Post transplant lymphoproliferative disorder polymorphic	PTLDP	7			4			3	14	1
Splenic Marginal Zone Lymphoma	SMZL	59		3	31		2	26	121	4
No classification recorded	NO CLASS	66			37			24	127	6
TOTAL		3779	25	651	1524	28	107	2073	8187	409

B NEO 'Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are processed from either BM or PB specimens or both per patient.

These samples are from tissue bank consented trial patients. Excess samples above MRD requirements were processed & stored and are available for approved researchers

B-CELL NEOPLASM (B NEO) 'Trial' Breakdown		Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Tissue	Serum	Total Sample Numbers	Total Patient Numbers
ALL5	TOTAL	ALL5	30		4				14	48	1
CLL2	TOTAL	CLL2			5					5	2
CLL5	TOTAL	CLL5	154		81	85			28	348	12
CLL8 *(Dx samples only - reserved for LFA research applicants)	TOTAL	CLL8	41		142	274			49	506	50
LY03	TOTAL	LY03	5						8	13	1
LY05	TOTAL	LY05	8			2				10	1
NHL11	TOTAL	NHL11						3		3	2
NHL14	TOTAL	NHL14	128			31		1	26	186	22
NHL16	TOTAL	NHL16	32			5		7	22	66	11
' B NEO' TRIAL TOTAL			398		232	397		11	147	1185	102
GRAND TOTAL ('B NEO' Trial and Non Trial)			4177	25	883	1921	28	118	2220	9372	511

CMPD 'Trial' and 'Non Trial' Breakdown

Sample numbers include both diagnostic and follow up time points. Samples no's are from BM, PB or both per patient

CHRONIC MYELOPROLIFERATIVE (CMPD) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Chronic Idiopathic Myelofibrosis and myelofibrosis (with extramedullary haematopoiesis)	CIM	42		2	25	31	100	6
Chronic Myeloproliferative Disease – Unclassifiable	CMDU	29		6	6	11	52	4
Chronic Myeloid Leukaemia (incl. Chronic Phase and Blast Phase)	CML	937	4	479	686	292	2398	42
Chronic Neutrophilic Leukaemia	CNL	8		10	4	4	26	1
Essential Thrombocythemia	ET	204		27	66	76	373	30
Polycythemia Vera	PV	118		24	25	37	204	20
Transformed Myelofibrosis - From PV	TMPV	20		1	8	9	38	2
Transformed Myelofibrosis - From ET	TMET	20		2		12	34	4
Chronic Eosinophilic Leukaemia/ Hypereosinophilic syndrome	CEL/HES	8			9	4	21	1
'CMPD' TOTAL		1386	4	551	829	476	3246	110

CMPD 'Trial' and 'Non Trial' Breakdown

These samples below are from tissue bank consented trial patients. Excess samples above MRD requirements were processed & stored and are now available for approved researchers

CHRONIC MYELOPROLIFERATIVE (CMPD) 'Trial' Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
CML6 TOTAL	CML6	229	19	403	93	66	810	67
CML8 TOTAL	CML8	45			24	27	96	2
CML9 TOTAL	CML9	152		72	92	49	365	7
CMPD TRIAL TOTAL		426	19	475	209	142	1271	76
'CMPD' GRAND TOTAL (Trial and Non Trial)		1812	23	1026	1038	618	4517	186

HD 'Trial' and 'Non Trial' Breakdown

HODGKIN LYMPHOMA (HD) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Nodular Sclerosis Classical Hodgkin Lymphoma	NSCHL	30	18	4	4	14	70	9
Mixed Cellularity Classical Hodgkin Lymphoma	MCCHL	38	4		25	12	79	3
Lymphocyte Rich Classical Hodgkin Lymphoma	LRCHL		3				3	1
Lymphocyte Depleted Classical Hodgkin Lymphoma	LDCHL		4				4	1
Nodular Lymphocyte Predominant Hodgkin Lymphoma	NLPHL		6				6	3
' HD' TOTAL		68	35	4	29	26	162	17

HD3 'Trial' Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Plasma	Total Sample Numbers	Total Patient Numbers
HD3 TOTAL	HD3					193	193	89
TOTAL						193	193	89

GRAND TOTAL 'HD'	(Trial and Non Trial)	68	35	4	29	219	355	106
-------------------------	------------------------------	-----------	-----------	----------	-----------	------------	------------	------------

MDS 'Non Trial' and 'Trial' Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are from BM, PB or both per patient

MYELODYSPLASTIC SYNDROME (MDS) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Serum	Total Sample Numbers	Total Patient Numbers
Myelodysplastic Syndrome associated with isolated (del) 5q chromosome abnormality	MDP5q	11			1	1	7	20	2
Myelodysplastic Syndrome - Unclassifiable	MDSU	26			7	1	25	59	5
Refractory Anaemia	RA	7			5	1	2	15	1
Refractory Anaemia with Excess Blasts	RAEB	30	1	2	4	2	22	61	6
RAEB-1		46			13	2	27	88	9
RAEB-2		153		23	53	6	115	350	14
Refractory Anaemia with Ringed Sideroblasts	RARS	14		9	5	2	12	42	3
Refractory Cytopenia with Multilineage dysplasia	RCMD	119		1	22	5	92	239	22
'MDS' TOTAL		406	1	35	110	20	302	874	62

MDS3 'Trial' Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Serum	Total Sample Numbers	Total Patient Numbers
MDS3 TOTAL		162		29	46		90	327	17
TOTAL		162		29	46		90	327	17

GRAND TOTAL 'MDS' (Trial and Non Trial)		568	1	64	156	20	392	1201	79
--	--	------------	----------	-----------	------------	-----------	------------	-------------	-----------

T cell and NK cell Neoplasms 'Non Trial'

Classification Breakdown

Sample numbers include both diagnostic and follow up time points.
 Samples numbers are from BM, PB or both per patient

T CELL and NK CELL NEOPLASMS (T/NK) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
No classification recorded	NO CLASS	6					4	10	1
Angioimmunoblastic T cell Lymphoma	AITCL	70		5		41	37	153	6
Anaplastic Large Cell Lymphoma	ALCL	42	1	4		18	27	92	4
Hepatosplenic T-cell Lymphoma	HSTCL	8		2	2	2	8	22	2
Extranodal NK/T cell Lymphoma Nasal Type	NKTCL	12				2	5	19	2
Peripheral T-Cell Lymphoma Unspecified	PTCLU	29		1		13	16	59	2
Sezary Syndrome	SS	34				28	7	69	2
Adult T-cell leukaemia/lymphoma	ATLL	21			10	2	8	41	1
Precursor T Lymphoblastic Leukaemia/Lymphoma	TALL	319			96	131	168	714	8
T cell Large granular Lymphocytic Leukaemia	TLGL	32			2	9	18	61	6
T-cell Prolymphocytic Leukaemia	TPLL	75			41	60	11	187	2
'T/NK' GRAND TOTAL		648	1	12	151	306	309	1427	36

MDS/MPD and IDALP 'Non Trial' Classification Breakdown

MYELOYDYSPLASTIC/MYELOPROLIFERATIVE (MDS/MPD) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
MDS/MPD Unclassified	?	15		9	6	8	38	2
Atypical Chronic Myeloid leukaemia	ACML	11		9	9	3	32	1
Chronic Myelomonocytic Leukaemia	CMML	269		44	159	90	562	21
Myelodysplastic/Myeloproliferative – unclassifiable	MDS/MPDU	16			9	5	30	2
'MDS/MPD' TOTAL		311	0	62	183	106	662	26

IMMUNODEFICIENCY ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS (IDALP) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Post transplant Lymphoproliferative Disorders	PTLD	48	4		42	7	101	2
Methotrexate-associated lymphoproliferative Disorders	MTALPD	5			2	5	12	1
'IDALP' TOTAL		53	4	0	44	12	113	3

MAST, HIST and MISC 'Non Trial' Classification Breakdown

MASTOCYTOSIS (MAST) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Systemic mastocytosis with associated clonal , haematological non mast cell lineage disease	SMS	4			2	7	13	1
'MAST' TOTAL		4			2	7	13	1

HISTIOCYTIC and DENDRITIC CELL NEOPLASM (HIST) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Currently there are NO patient samples available for this diagnosis							0	0
'HIST' TOTAL		0	0	0	0	0	0	0

MISCELLANEOUS (MISC) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Patients and samples awaiting further information before being able to classify into major diagnostic group/s	MISC	73		6	26	59	164	10
'MISC' TOTAL		73	0	6	26	59	164	10